NANOMIX Corp
company.status.inactiveCIK 1473579fmd_1K74W35JY9DA0M6CYHSC7QE9Y1Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Dec 31, 2022, 51 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Gross profit | 0 | 0 | (0) | 0 | – | – | – | – | – | – |
| Research and development | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 3 | 3 |
| Selling, general and administrative | 4 | 3 | 2 | 1 | 1 | 2 | 2 | 1 | 3 | 5 |
| Total operating expenses | 5 | 5 | 2 | 1 | 1 | 3 | 4 | 5 | 6 | 8 |
| Operating income | (5) | (5) | (2) | (1) | (1) | (3) | (4) | (5) | (6) | (8) |
| Interest expense | – | – | – | – | – | 0 | 0 | 0 | 1 | – |
| Other non-operating income (expense) | 0 | (0) | (0) | (0) | – | – | – | (1) | (4) | (4) |
| Income before taxes | – | – | (2) | (4) | (2) | (4) | (4) | (6) | (9) | (12) |
| Income tax expense | – | – | – | 0 | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | (4) | – | – | – | – | – | – |
| Net income | (1) | (5) | (2) | (4) | (2) | (4) | (4) | (1) | (9) | (12) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | (9) | (13) |